Share:
A drug discovery company with ownership stakes in several public and private biopharmaceutical companies is going public with a SPAC deal announced Monday morning.
The SPAC Deal: Roviant Sciences announced a SPAC deal with
Montes Archimedes Acquisition Corp (NASDAQ: MAAC). The deal values the company at an enterprise value of $5 billion.
A $200 million PIPE is backed by companies including Softbank Group Corp., Fidelity Management & Research Co., Sumitomo Dainippon Pharma and
Palantir Technologies Inc (NYSE: PLTR).
Shares of the new company will trade as ROIV on the Nasdaq with an anticipated closing date in the third quarter.
A percentage of current ownership shares will have a three-year lock-up and earn-outs based on $15 and $20 price points. Current Montes Archimedes acquisition shareholders will own 5.6% of the company after the merger.